More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain

Detalles Bibliográficos
Autor principal: Curtiss, Frederic R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2006
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437638/
https://www.ncbi.nlm.nih.gov/pubmed/16792441
http://dx.doi.org/10.18553/jmcp.2006.12.4.343
_version_ 1785092575560990720
author Curtiss, Frederic R.
author_facet Curtiss, Frederic R.
author_sort Curtiss, Frederic R.
collection PubMed
description
format Online
Article
Text
id pubmed-10437638
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104376382023-08-21 More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain Curtiss, Frederic R. J Manag Care Pharm Editorials Academy of Managed Care Pharmacy 2006-05 /pmc/articles/PMC10437638/ /pubmed/16792441 http://dx.doi.org/10.18553/jmcp.2006.12.4.343 Text en Copyright © 2006, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Editorials
Curtiss, Frederic R.
More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
title More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
title_full More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
title_fullStr More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
title_full_unstemmed More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
title_short More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
title_sort more evolution of the evidence in asthma disease management-smart versus goal clinical trials debate the cost-benefit of laba while the value of leukotriene modifiers, particularly montelukast, is uncertain
topic Editorials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437638/
https://www.ncbi.nlm.nih.gov/pubmed/16792441
http://dx.doi.org/10.18553/jmcp.2006.12.4.343
work_keys_str_mv AT curtissfredericr moreevolutionoftheevidenceinasthmadiseasemanagementsmartversusgoalclinicaltrialsdebatethecostbenefitoflabawhilethevalueofleukotrienemodifiersparticularlymontelukastisuncertain

Ejemplares similares